voriconazole Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
systemic antifungal agents, miconazole derivatives	2846	137234-62-9

Description:

Molecule	Description
Molfile Inchi Smiles Synonyms: voriconazole voriconazol vfend UK109496 UK-109496 UK 109496	A triazole antifungal agent that specifically inhibits STEROL 14-ALPHA-DEMETHYLASE and CYTOCHROME P-450 CYP3A. Molecular weight: 349.32 Formula: C16H14F3N5O CLOGP: 0.52 LIPINSKI: 0 HAC: 6 HDO: 1 TPSA: 76.72 ALOGS: -3.55 ROTB: 5 Status: OFP Legend: OFP - off patent OFM - off market ONP - on patent

Drug dosage:

Dose	Unit	Route
0.40	g	O
0.40	g	P

ADMET properties:

Property	Value	Reference
BDDCS (Biopharmaceutical Drug Disposition Classification System)	2	Benet LZ, Broccatelli F, Oprea TI
S (Water solubility)	0.39 mg/mL	Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine)	1.50 %	Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose)	34.35 µM/kg/day	Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability)	96 %	Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H
Vd (Volume of distribution)	2.20 L/kg	Lombardo F, Berellini G, Obach RS
CL (Clearance)	8.30 mL/min/kg	Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma)	0.42 %	Lombardo F, Berellini G, Obach RS
t_half (Half-life)	5.60 hours	Lombardo F, Berellini G, Obach RS

Approvals:

Date	Agency	Company	Orphan
May 24, 2002	FDA	PF PRISM CV

FDA Adverse Event Reporting System (Female)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Bronchopulmonary aspergillosis	646.10	15.75	203	19487	7293	46659079
Aspergillus infection	521.28	15.75	169	19521	6721	46659651
Drug interaction	329.88	15.75	416	19274	202678	46463694
Mucormycosis	283.27	15.75	82	19608	2210	46664162
Periostitis	280.11	15.75	53	19637	182	46666190
Multiple organ dysfunction syndrome	197.35	15.75	168	19522	51542	46614830
Drug level increased	186.81	15.75	109	19581	18332	46648040
Drug resistance	184.82	15.75	106	19584	17262	46649110
Photosensitivity reaction	183.10	15.75	95	19595	12697	46653675
Septic shock	165.67	15.75	160	19530	57733	46608639
Pneumonia fungal	164.45	15.75	63	19627	4097	46662275
Febrile neutropenia	150.11	15.75	192	19498	94435	46571937
Drug level below therapeutic	143.98	15.75	53	19637	3084	46663288
Fungal infection	135.85	15.75	107	19583	29413	46636959
Drug level decreased	123.95	15.75	57	19633	5855	46660517
Respiratory failure	122.31	15.75	174	19516	94642	46571730
Cerebral aspergillosis	118.72	15.75	28	19662	326	46666046
Acute myeloid leukaemia	118.32	15.75	77	19613	15701	46650671
Graft versus host disease	118.06	15.75	57	19633	6531	46659841
Cholestasis	107.92	15.75	90	19600	26803	46639569
Dilatation intrahepatic duct acquired	106.67	15.75	30	19660	726	46665646
Fatigue	104.77	15.75	64	19626	608633	46057739
Scedosporium infection	102.88	15.75	27	19663	499	46665873
Systemic mycosis	96.24	15.75	29	19661	900	46665472
Hallucination, visual	93.64	15.75	70	19620	17803	46648569
Actinic keratosis	85.25	15.75	33	19657	2206	46664166
Pathogen resistance	83.82	15.75	44	19646	6016	46660356
Pancytopenia	82.71	15.75	137	19553	84921	46581451
Fusarium infection	81.84	15.75	23	19667	555	46665817
Visual impairment	80.98	15.75	119	19571	66570	46599802
Hallucination	80.12	15.75	102	19588	49849	46616523
Pain	79.38	15.75	52	19638	476896	46189476
Venoocclusive liver disease	76.83	15.75	37	19653	4214	46662158
Fluoride increased	71.54	15.75	12	19678	15	46666357
Hepatotoxicity	71.23	15.75	69	19621	24940	46641432
Photodermatosis	71.08	15.75	19	19671	378	46665994
Drug ineffective	70.04	15.75	506	19184	677332	45989040
Geotrichum infection	67.82	15.75	19	19671	453	46665919
Blood bilirubin increased	66.52	15.75	77	19613	34107	46632265
Pyrexia	65.14	15.75	305	19385	348497	46317875
Sepsis	62.79	15.75	161	19529	135853	46530519
Acute graft versus host disease in intestine	61.06	15.75	24	19666	1671	46664701
Hypertrophic osteoarthropathy	60.30	15.75	11	19679	29	46666343
Squamous cell carcinoma of skin	59.00	15.75	33	19657	5114	46661258
Pneumonia	53.49	15.75	305	19385	376015	46290357
Keratitis fungal	53.19	15.75	12	19678	113	46666259
Neurotoxicity	53.14	15.75	45	19645	13672	46652700
Fall	51.83	15.75	38	19652	329059	46337313
Graft versus host disease in gastrointestinal tract	51.62	15.75	24	19666	2526	46663846
Fungaemia	50.70	15.75	22	19668	1969	46664403
Acute graft versus host disease in liver	49.59	15.75	16	19674	624	46665748
Cytomegalovirus viraemia	49.40	15.75	28	19662	4450	46661922
Acute graft versus host disease	49.38	15.75	27	19663	4003	46662369
Immunosuppressant drug level increased	48.74	15.75	25	19665	3257	46663115
Hepatic function abnormal	48.53	15.75	66	19624	34355	46632017
Blood alkaline phosphatase increased	48.51	15.75	71	19619	39538	46626834
Acute graft versus host disease in skin	48.04	15.75	24	19666	2958	46663414
Acute myeloid leukaemia recurrent	47.61	15.75	19	19671	1377	46664995
Fungal test positive	47.56	15.75	15	19675	543	46665829
Product use in unapproved indication	47.06	15.75	112	19578	90161	46576211
Cytomegalovirus infection	46.00	15.75	47	19643	18097	46648275
Gamma-glutamyltransferase increased	44.96	15.75	61	19629	31679	46634693
Headache	44.50	15.75	84	19606	478268	46188104
Squamous cell carcinoma	43.98	15.75	32	19658	7804	46658568
Strongyloidiasis	41.12	15.75	15	19675	850	46665522
Graft versus host disease in skin	40.96	15.75	20	19670	2347	46664025
Acute respiratory distress syndrome	40.34	15.75	48	19642	21874	46644498
Drug hypersensitivity	39.87	15.75	27	19663	243798	46422574
Fluorosis	39.39	15.75	7	19683	15	46666357
Chronic graft versus host disease	38.29	15.75	20	19670	2705	46663667
Product dose omission issue	37.82	15.75	12	19678	168508	46497864
Joint swelling	36.96	15.75	12	19678	166061	46500311
Corneal perforation	36.57	15.75	12	19678	494	46665878
Liver function test abnormal	36.24	15.75	68	19622	46419	46619953
Phaeohyphomycosis	35.95	15.75	10	19680	232	46666140
Thrombotic microangiopathy	35.82	15.75	29	19661	8277	46658095
Halo vision	35.80	15.75	11	19679	365	46666007
Lentigo	35.40	15.75	10	19680	246	46666126
Lung transplant rejection	35.31	15.75	13	19677	756	46665616
Arthralgia	34.77	15.75	63	19627	364540	46301832
Pain in extremity	34.45	15.75	35	19655	258645	46407727
Posterior reversible encephalopathy syndrome	34.41	15.75	37	19653	15104	46651268
Dizziness	34.11	15.75	57	19633	340357	46326015
Pseudomonas infection	33.73	15.75	30	19660	9728	46656644
Hypertransaminasaemia	33.68	15.75	20	19670	3468	46662904
Cerebral fungal infection	33.66	15.75	7	19683	43	46666329
Dyschromatopsia	33.60	15.75	10	19680	297	46666075
Neutropenia	32.52	15.75	133	19557	143071	46523301
Adenovirus infection	32.04	15.75	18	19672	2812	46663560
Lower respiratory tract infection fungal	31.42	15.75	9	19681	233	46666139
Brain abscess	31.21	15.75	15	19675	1700	46664672
Aspergillus test	30.92	15.75	5	19685	4	46666368
Pruritus	30.91	15.75	34	19656	242318	46424054
Granulomatous liver disease	30.83	15.75	12	19678	814	46665558
Hepatocellular injury	30.62	15.75	49	19641	29473	46636899
Musculoskeletal stiffness	30.50	15.75	3	19687	97990	46568382
Pulmonary alveolar haemorrhage	30.43	15.75	20	19670	4142	46662230
Platelet count decreased	30.33	15.75	102	19588	99922	46566450
Altered state of consciousness	30.26	15.75	43	19647	23305	46643067
Solar lentigo	30.16	15.75	11	19679	623	46665749
Infective aneurysm	30.10	15.75	10	19680	428	46665944
Systemic candida	29.94	15.75	17	19673	2710	46663662
Exposure during pregnancy	29.62	15.75	5	19685	108207	46558165
Pneumonia bacterial	29.62	15.75	24	19666	6855	46659517
Immunosuppressant drug level decreased	29.42	15.75	12	19678	920	46665452
Enterococcal infection	29.29	15.75	24	19666	6963	46659409
Bone marrow failure	29.08	15.75	48	19642	29621	46636751
Chromatopsia	28.86	15.75	10	19680	487	46665885
Aspergillus test positive	28.75	15.75	9	19681	318	46666054
Encephalopathy	28.53	15.75	51	19639	33538	46632834
Acute lymphocytic leukaemia recurrent	28.37	15.75	15	19675	2080	46664292
Nasopharyngitis	28.03	15.75	15	19675	153983	46512389
Diarrhoea	27.59	15.75	132	19558	559470	46106902
Alanine aminotransferase increased	27.53	15.75	91	19599	88360	46578012
Toxic epidermal necrolysis	27.36	15.75	40	19650	22238	46644134
Abdominal discomfort	27.11	15.75	15	19675	151150	46515222
Nausea	26.92	15.75	175	19515	687279	45979093
Trichosporon infection	26.77	15.75	8	19682	241	46666131
Coccidioidomycosis	26.62	15.75	11	19679	872	46665500
Haemoptysis	26.52	15.75	43	19647	26146	46640226
Venoocclusive disease	26.47	15.75	14	19676	1942	46664430
Fungal endocarditis	26.46	15.75	8	19682	251	46666121
Renal impairment	26.33	15.75	80	19610	74292	46592080
Aspartate aminotransferase increased	26.33	15.75	83	19607	78617	46587755
Delirium	26.01	15.75	52	19638	37176	46629196
Candida infection	25.98	15.75	39	19651	22201	46644171
Graft versus host disease in liver	25.77	15.75	9	19681	449	46665923
Primary myelofibrosis	25.75	15.75	6	19684	66	46666306
Colour blindness	25.71	15.75	8	19682	277	46666095
Leukaemia recurrent	25.50	15.75	12	19678	1297	46665075
Dermatitis bullous	25.43	15.75	23	19667	7620	46658752
Urticaria	25.38	15.75	9	19681	117883	46548489
Photophobia	25.37	15.75	31	19659	14513	46651859
Arthropathy	25.32	15.75	3	19687	84697	46581675
Cytokine release syndrome	25.31	15.75	21	19669	6202	46660170
Obliterative bronchiolitis	24.86	15.75	13	19677	1762	46664610
Urinary tract infection	24.81	15.75	34	19656	220232	46446140
Disseminated intravascular coagulation	24.62	15.75	35	19655	18970	46647402
Leukaemia	24.49	15.75	16	19674	3279	46663093
Graft versus host disease in lung	24.46	15.75	8	19682	326	46666046
Malaise	24.35	15.75	66	19624	331166	46335206
Leukoencephalopathy	23.95	15.75	17	19673	3987	46662385
Peripheral swelling	23.88	15.75	19	19671	158052	46508320
Infective pulmonary exacerbation of cystic fibrosis	23.84	15.75	26	19664	10781	46655591
Anxiety	23.77	15.75	25	19665	181932	46484440
Pseudoaldosteronism	23.73	15.75	5	19685	33	46666339
Pneumothorax	23.63	15.75	30	19660	14599	46651773
Myocardial infarction	23.61	15.75	6	19684	97522	46568850
Maternal exposure during pregnancy	23.54	15.75	7	19683	102542	46563830
Disease progression	23.30	15.75	88	19602	91212	46575160
Chronic graft versus host disease in skin	23.08	15.75	9	19681	613	46665759
Stenotrophomonas infection	23.08	15.75	12	19678	1608	46664764
Asthenia	22.85	15.75	62	19628	311013	46355359
Swelling	22.84	15.75	12	19678	124499	46541873
Staphylococcal infection	22.67	15.75	48	19642	35723	46630649
Pulmonary haemorrhage	22.48	15.75	20	19670	6485	46659887
Procalcitonin increased	22.38	15.75	9	19681	665	46665707
Post transplant lymphoproliferative disorder	22.21	15.75	16	19674	3840	46662532
Therapeutic product effect decreased	22.20	15.75	4	19686	82597	46583775
Electrocardiogram QT prolonged	21.84	15.75	59	19631	51266	46615106
Thrombocytopenia	21.56	15.75	108	19582	126473	46539899
Depression	21.52	15.75	24	19666	170080	46496292
Bronchopulmonary aspergillosis allergic	21.50	15.75	9	19681	737	46665635
Disseminated cryptococcosis	21.38	15.75	7	19683	286	46666086
Tonsillitis bacterial	21.18	15.75	6	19684	149	46666223
Tracheobronchitis	21.07	15.75	10	19680	1102	46665270
Chronic papillomatous dermatitis	21.06	15.75	5	19685	60	46666312
Bacterial sepsis	21.00	15.75	15	19675	3552	46662820
Palpitations	20.97	15.75	7	19683	95252	46571120
Muscle spasms	20.96	15.75	13	19677	123100	46543272
Drug-induced liver injury	20.88	15.75	38	19652	25330	46641042
Scintillating scotoma	20.74	15.75	6	19684	161	46666211
Hepatic candidiasis	20.66	15.75	4	19686	16	46666356
Aspergilloma	20.43	15.75	6	19684	170	46666202
Liver disorder	20.24	15.75	47	19643	37199	46629173
Encephalitis	20.17	15.75	20	19670	7428	46658944
Renal failure	20.11	15.75	98	19592	113496	46552876
Abdominal pain upper	20.08	15.75	19	19671	145286	46521086
Rash	20.01	15.75	80	19610	356432	46309940
Septal panniculitis	19.97	15.75	5	19685	76	46666296
Tuberculosis gastrointestinal	19.93	15.75	7	19683	355	46666017
Torsade de pointes	19.75	15.75	25	19665	12129	46654243
Bacteraemia	19.69	15.75	27	19663	14152	46652220
Acute lymphocytic leukaemia	19.48	15.75	13	19677	2760	46663612
Blood pressure increased	19.41	15.75	15	19675	126651	46539721
Eye abscess	19.28	15.75	5	19685	88	46666284
Agranulocytosis	19.24	15.75	34	19656	22151	46644221
Hepatosplenic candidiasis	19.03	15.75	6	19684	217	46666155
Aplastic anaemia	18.99	15.75	19	19671	7134	46659238
Hallucination, auditory	18.88	15.75	23	19667	10733	46655639
Cystitis haemorrhagic	18.81	15.75	14	19676	3533	46662839
Pleural effusion	18.77	15.75	77	19613	82875	46583497
Dermatitis exfoliative	18.62	15.75	17	19673	5699	46660673
Fungal skin infection	18.62	15.75	14	19676	3588	46662784
Back pain	18.49	15.75	38	19652	210001	46456371
Bacterial infection	18.32	15.75	28	19662	16188	46650184
Drug clearance decreased	18.28	15.75	9	19681	1075	46665297
Cholecystitis acute	18.15	15.75	19	19671	7519	46658853
Acute kidney injury	18.08	15.75	165	19525	235690	46430682
Death	17.86	15.75	218	19472	335330	46331042
Osteomyelitis fungal	17.78	15.75	3	19687	4	46666368
Treatment failure	17.70	15.75	82	19608	93005	46573367
Infection reactivation	17.70	15.75	8	19682	789	46665583
Endophthalmitis	17.52	15.75	13	19677	3265	46663107
Laryngeal inflammation	17.47	15.75	5	19685	129	46666243
Skin cancer	17.36	15.75	20	19670	8803	46657569
Gastrooesophageal reflux disease	17.19	15.75	5	19685	74339	46592033
Chest pain	17.18	15.75	30	19660	176294	46490078
Hypersensitivity	17.12	15.75	23	19667	150298	46516074
Dyspepsia	16.99	15.75	4	19686	68468	46597904
Cytomegalovirus test positive	16.93	15.75	12	19678	2808	46663564
Sinusitis	16.75	15.75	18	19672	129750	46536622
Stem cell transplant	16.72	15.75	10	19680	1756	46664616
Drug ineffective for unapproved indication	16.68	15.75	27	19663	16386	46649986
Differentiation syndrome	16.67	15.75	8	19682	903	46665469
Neutrophil count decreased	16.58	15.75	48	19642	43378	46622994
Extraskeletal ossification	16.48	15.75	4	19686	53	46666319
Abscess fungal	16.15	15.75	4	19686	58	46666314
Anal infection	16.08	15.75	4	19686	59	46666313
Shock haemorrhagic	16.05	15.75	19	19671	8605	46657767
Weight increased	16.01	15.75	28	19662	164445	46501927
Acinetobacter infection	15.98	15.75	9	19681	1413	46664959
Respiratory distress	15.97	15.75	39	19651	31877	46634495
Cytopenia	15.95	15.75	18	19672	7750	46658622
Liver sarcoidosis	15.92	15.75	3	19687	10	46666362
Sunburn	15.80	15.75	11	19679	2501	46663871

FDA Adverse Event Reporting System (Male)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Bronchopulmonary aspergillosis	764.03	14.16	336	32088	11948	29908106
Aspergillus infection	712.51	14.16	303	32121	9911	29910143
Photosensitivity reaction	621.65	14.16	271	32153	9423	29910631
Drug interaction	437.21	14.16	776	31648	198792	29721262
Drug level increased	401.23	14.16	249	32175	18105	29901949
Periostitis	329.52	14.16	72	32352	181	29919873
Mucormycosis	314.08	14.16	140	32284	5128	29914926
Fungal infection	308.59	14.16	189	32235	13411	29906643
Cerebral aspergillosis	294.30	14.16	93	32331	1265	29918789
Actinic keratosis	251.42	14.16	107	32317	3496	29916558
Drug ineffective	226.67	14.16	843	31581	339544	29580510
Scedosporium infection	214.99	14.16	63	32361	652	29919402
Drug resistance	211.71	14.16	175	32249	19958	29900096
Multiple organ dysfunction syndrome	197.01	14.16	290	32134	63197	29856857
Hallucination, visual	192.63	14.16	151	32273	15962	29904092
Squamous cell carcinoma of skin	158.27	14.16	107	32317	8988	29911066
Hallucination	154.87	14.16	226	32198	48833	29871221
Graft versus host disease	152.25	14.16	109	32315	10041	29910013
Squamous cell carcinoma	142.21	14.16	105	32319	10145	29909909
Photodermatosis	138.18	14.16	40	32384	395	29919659
Hepatotoxicity	137.41	14.16	131	32293	18014	29902040
Fatigue	133.98	14.16	92	32332	320581	29599473
Pneumonia fungal	130.85	14.16	79	32345	5454	29914600
Respiratory failure	127.98	14.16	314	32110	100328	29819726
Condition aggravated	126.16	14.16	381	32043	137485	29782569
Septic shock	125.24	14.16	237	32187	63370	29856684
Pathogen resistance	120.84	14.16	88	32336	8322	29911732
Febrile neutropenia	105.28	14.16	303	32121	106390	29813664
Cholestasis	98.32	14.16	128	32296	24822	29895232
Completed suicide	94.13	14.16	3	32421	99489	29820565
Systemic mycosis	91.12	14.16	38	32386	1178	29918876
Choroiditis	90.25	14.16	34	32390	801	29919253
Hepatic function abnormal	89.67	14.16	162	32262	41783	29878271
Drug level below therapeutic	86.89	14.16	51	32373	3341	29916713
Visual impairment	85.69	14.16	133	32291	30305	29889749
Fluoride increased	84.55	14.16	18	32406	38	29920016
Myocardial infarction	83.86	14.16	17	32407	125608	29794446
Cheilitis	82.81	14.16	43	32381	2213	29917841
Solar lentigo	80.84	14.16	25	32399	315	29919739
Endophthalmitis	80.51	14.16	49	32375	3431	29916623
Fall	73.34	14.16	54	32370	181818	29738236
Drug level decreased	72.81	14.16	56	32368	5749	29914305
Drug abuse	72.55	14.16	4	32420	82068	29837986
Fungaemia	71.93	14.16	39	32385	2192	29917862
Fusarium infection	68.96	14.16	30	32394	1034	29919020
Dysplastic naevus	67.13	14.16	22	32402	338	29919716
Phaeohyphomycosis	66.17	14.16	27	32397	791	29919263
Candida infection	65.53	14.16	82	32342	15280	29904774
Immunosuppressant drug level increased	64.83	14.16	48	32376	4654	29915400
Drug level above therapeutic	64.46	14.16	40	32384	2899	29917155
Acute myeloid leukaemia	64.21	14.16	88	32336	17918	29902136
Product dose omission issue	64.12	14.16	11	32413	91620	29828434
Mycotic endophthalmitis	62.25	14.16	14	32410	42	29920012
Pain	61.28	14.16	58	32366	172583	29747471
Graft versus host disease in gastrointestinal tract	60.40	14.16	39	32385	3030	29917024
Aspergilloma	60.34	14.16	20	32404	319	29919735
Fluorosis	55.32	14.16	13	32411	50	29920004
Asthenia	55.17	14.16	97	32327	221193	29698861
Nephropathy toxic	53.92	14.16	62	32362	10577	29909477
Acute myeloid leukaemia recurrent	52.47	14.16	28	32396	1524	29918530
Product use in unapproved indication	52.26	14.16	187	32237	73506	29846548
Dyspnoea	52.04	14.16	186	32238	333109	29586945
Inappropriate antidiuretic hormone secretion	51.99	14.16	63	32361	11359	29908695
Treatment failure	50.26	14.16	114	32310	34565	29885489
Depression	49.51	14.16	18	32406	90419	29829635
Hepatocellular injury	47.71	14.16	93	32331	25378	29894676
Trichosporon infection	47.57	14.16	20	32404	633	29919421
Disseminated mucormycosis	47.41	14.16	14	32410	149	29919905
Dyschromatopsia	46.84	14.16	16	32408	281	29919773
Pseudomonas infection	46.38	14.16	57	32367	10425	29909629
Nausea	46.13	14.16	166	32258	296791	29623263
Anxiety	45.74	14.16	20	32404	89851	29830203
Brain abscess	45.34	14.16	31	32393	2650	29917404
Neurological symptom	44.87	14.16	34	32390	3413	29916641
Neurotoxicity	44.86	14.16	63	32361	13119	29906935
Chest pain	44.73	14.16	37	32387	117590	29802464
Dizziness	44.54	14.16	90	32334	194819	29725235
Diarrhoea	44.20	14.16	199	32225	333904	29586150
Liver disorder	43.39	14.16	98	32326	29624	29890430
Disseminated intravascular coagulation	42.80	14.16	82	32342	22089	29897965
Cardiac failure congestive	42.61	14.16	19	32405	84388	29835666
Constipation	42.33	14.16	36	32388	112870	29807184
Product compounding quality issue	41.65	14.16	9	32415	21	29920033
Leukaemia recurrent	41.38	14.16	24	32400	1537	29918517
Cytokine release syndrome	40.74	14.16	52	32372	9881	29910173
Renal ischaemia	40.73	14.16	17	32407	528	29919526
Central nervous system fungal infection	40.51	14.16	14	32410	255	29919799
Uveitis	40.41	14.16	39	32385	5438	29914616
Pruritus	40.41	14.16	41	32383	118163	29801891
Pain in extremity	40.29	14.16	36	32388	110185	29809869
Geotrichum infection	39.36	14.16	16	32408	464	29919590
Alternaria infection	38.27	14.16	14	32410	303	29919751
Visual acuity reduced	37.46	14.16	64	32360	15782	29904272
Cytomegalovirus viraemia	37.10	14.16	38	32386	5691	29914363
Arthralgia	37.08	14.16	56	32368	135735	29784319
Intraocular pressure increased	36.92	14.16	36	32388	5084	29914970
Enterococcal infection	36.84	14.16	45	32379	8179	29911875
Dehydration	36.66	14.16	48	32376	123491	29796563
Burns second degree	36.20	14.16	14	32410	355	29919699
Enterococcal sepsis	36.07	14.16	22	32402	1546	29918508
Graft versus host disease in skin	35.26	14.16	29	32395	3278	29916776
Acute graft versus host disease in liver	35.17	14.16	20	32404	1234	29918820
Hepatitis cholestatic	35.14	14.16	43	32381	7829	29912225
Blood pressure increased	35.05	14.16	17	32407	71911	29848143
Aspergillus test positive	34.57	14.16	14	32410	402	29919652
Product contamination microbial	34.41	14.16	16	32408	646	29919408
Nocardiosis	34.15	14.16	29	32395	3426	29916628
Drug ineffective for unapproved indication	34.09	14.16	50	32374	10830	29909224
Eye infection fungal	34.09	14.16	13	32411	317	29919737
Rheumatoid arthritis	33.53	14.16	3	32421	41194	29878860
Blood alkaline phosphatase increased	33.49	14.16	92	32332	31395	29888659
Acute graft versus host disease in skin	33.02	14.16	32	32392	4484	29915570
Pneumonia	33.01	14.16	526	31898	333780	29586274
Photophobia	32.98	14.16	36	32388	5800	29914254
Scopulariopsis infection	32.93	14.16	10	32414	118	29919936
Peripheral swelling	32.01	14.16	13	32411	61061	29858993
Acute respiratory distress syndrome	31.63	14.16	75	32349	23397	29896657
Septic embolus	31.55	14.16	18	32406	1117	29918937
Cystitis haemorrhagic	31.45	14.16	32	32392	4755	29915299
Intentional overdose	31.26	14.16	4	32420	41477	29878577
Post transplant lymphoproliferative disorder	30.45	14.16	33	32391	5273	29914781
Vomiting	30.16	14.16	129	32295	219689	29700365
Nasopharyngitis	30.08	14.16	13	32411	58836	29861218
Pulmonary cavitation	30.02	14.16	15	32409	711	29919343
Cerebrovascular accident	29.62	14.16	28	32396	83449	29836605
Hyperhidrosis	29.56	14.16	18	32406	67072	29852982
Hypertension	29.45	14.16	54	32370	121300	29798754
Acute graft versus host disease	29.42	14.16	34	32390	5830	29914224
Pseudoporphyria	29.28	14.16	11	32413	257	29919797
Cytomegalovirus infection	29.08	14.16	73	32351	23601	29896453
Hepatic failure	29.07	14.16	92	32332	33951	29886103
Central nervous system lesion	29.01	14.16	31	32393	4875	29915179
Weight decreased	28.57	14.16	77	32347	150844	29769210
Torsade de pointes	28.48	14.16	37	32387	7153	29912901
Acute myocardial infarction	28.19	14.16	11	32413	52928	29867126
Malaise	28.11	14.16	90	32334	166872	29753182
Toxic optic neuropathy	27.94	14.16	14	32410	668	29919386
Urinary bladder rupture	27.82	14.16	7	32417	38	29920016
Lip squamous cell carcinoma	27.63	14.16	8	32416	79	29919975
Drug-induced liver injury	27.61	14.16	67	32357	21207	29898847
Back pain	27.33	14.16	43	32381	102553	29817501
Lentigo	27.16	14.16	11	32413	316	29919738
Transmission of an infectious agent via product	26.30	14.16	9	32415	159	29919895
Xanthopsia	26.25	14.16	9	32415	160	29919894
Headache	26.23	14.16	105	32319	182201	29737853
Photopsia	26.17	14.16	19	32405	1787	29918267
Pyrexia	25.95	14.16	455	31969	294034	29626020
Gallbladder empyema	25.94	14.16	7	32417	52	29920002
Acanthamoeba keratitis	25.92	14.16	8	32416	100	29919954
Neutropenia	25.88	14.16	232	32192	128308	29791746
Sepsis	25.88	14.16	257	32167	146138	29773916
Psoriasis	25.86	14.16	7	32417	42499	29877555
Urinary tract infection	25.79	14.16	25	32399	73634	29846420
Disease recurrence	25.65	14.16	51	32373	14110	29905944
Fungal skin infection	25.25	14.16	21	32403	2411	29917643
Muscle spasms	25.12	14.16	20	32404	64818	29855236
Gallbladder oedema	24.85	14.16	9	32415	189	29919865
Tongue necrosis	24.78	14.16	6	32418	27	29920027
Gamma-glutamyltransferase increased	24.77	14.16	79	32345	29271	29890783
Nervous system disorder	23.59	14.16	47	32377	13022	29907032
Chromatopsia	23.43	14.16	9	32415	224	29919830
Arthritis fungal	23.42	14.16	7	32417	78	29919976
Inappropriate schedule of product administration	23.32	14.16	7	32417	39721	29880333
Eye pain	23.24	14.16	44	32380	11745	29908309
Pulmonary alveolar haemorrhage	23.21	14.16	32	32392	6549	29913505
Dyspnoea exertional	23.18	14.16	5	32419	35425	29884629
BK virus infection	23.07	14.16	26	32398	4338	29915716
Hypertrophic osteoarthropathy	23.02	14.16	7	32417	83	29919971
Rectal haemorrhage	22.72	14.16	5	32419	34934	29885120
Dyspepsia	22.67	14.16	3	32421	30326	29889728
Abscess fungal	22.64	14.16	8	32416	156	29919898
Chronic graft versus host disease	22.57	14.16	25	32399	4094	29915960
Retinal ischaemia	22.53	14.16	10	32414	362	29919692
Pulmonary embolism	22.51	14.16	31	32393	78104	29841950
Cytomegalovirus enterocolitis	22.49	14.16	13	32411	827	29919227
Pulmonary haemorrhage	22.28	14.16	38	32386	9354	29910700
Gastrooesophageal reflux disease	22.27	14.16	4	32420	32251	29887803
Urticaria	22.23	14.16	16	32408	54590	29865464
Fungal endocarditis	22.14	14.16	8	32416	167	29919887
Klebsiella infection	22.08	14.16	32	32392	6855	29913199
Infectious pleural effusion	22.06	14.16	18	32406	2012	29918042
Asthma	21.92	14.16	6	32418	36168	29883886
Necrotising retinitis	21.51	14.16	12	32412	713	29919341
Acute graft versus host disease in intestine	21.37	14.16	19	32405	2386	29917668
Lung infiltration	21.29	14.16	44	32380	12515	29907539
Ureaplasma infection	21.21	14.16	8	32416	189	29919865
Systemic candida	20.99	14.16	20	32404	2744	29917310
Altered state of consciousness	20.97	14.16	58	32366	19861	29900193
Pulmonary mucormycosis	20.94	14.16	10	32414	429	29919625
Lower respiratory tract infection fungal	20.93	14.16	11	32413	580	29919474
Cerebral fungal infection	20.90	14.16	8	32416	197	29919857
Sunburn	20.82	14.16	16	32408	1640	29918414
Pulmonary mass	20.74	14.16	40	32384	10822	29909232
Osteomyelitis fungal	20.68	14.16	8	32416	203	29919851
Pancytopenia	20.56	14.16	160	32264	84892	29835162
Burns first degree	20.55	14.16	4	32420	4	29920050
Peptic ulcer haemorrhage	20.19	14.16	10	32414	465	29919589
Scintillating scotoma	20.05	14.16	5	32419	26	29920028
Organising pneumonia	19.92	14.16	26	32398	5048	29915006
Neurological decompensation	19.91	14.16	18	32406	2310	29917744
Meningitis coccidioides	19.90	14.16	5	32419	27	29920027
Musculoskeletal stiffness	19.86	14.16	7	32417	35874	29884180
Leukaemia	19.79	14.16	21	32403	3276	29916778
Angina pectoris	19.65	14.16	4	32420	29514	29890540
Citrobacter infection	19.36	14.16	10	32414	509	29919545
Colour blindness acquired	19.30	14.16	6	32418	77	29919977
Eye abscess	19.11	14.16	7	32417	152	29919902
Bacterial sepsis	18.97	14.16	25	32399	4901	29915153
Splenic candidiasis	18.69	14.16	6	32418	86	29919968
Syncope	18.67	14.16	40	32384	84863	29835191
Halo vision	18.46	14.16	7	32417	168	29919886
Hyperammonaemia	18.21	14.16	26	32398	5494	29914560
Retinal haemorrhage	18.15	14.16	24	32400	4719	29915335
International normalised ratio increased	18.14	14.16	15	32409	47724	29872330
Fibrinous bronchitis	18.04	14.16	4	32420	11	29920043
Transaminases increased	17.87	14.16	61	32363	23396	29896658
Oral papilloma	17.79	14.16	4	32420	12	29920042
Neuroendocrine carcinoma of the skin	17.76	14.16	10	32414	605	29919449
Abdominal pain	17.72	14.16	81	32343	135573	29784481
Transplant rejection	17.70	14.16	34	32390	9172	29910882
Macular opacity	17.49	14.16	3	32421	0	29920054
Inhibitory drug interaction	17.24	14.16	14	32410	1554	29918500
Intentional product misuse	17.18	14.16	8	32416	34659	29885395
Drug hypersensitivity	17.05	14.16	30	32394	68489	29851565
Decreased appetite	17.03	14.16	94	32330	149816	29770238
Disease progression	17.01	14.16	146	32278	79728	29840326
Hypoxia	16.96	14.16	99	32325	47755	29872299
Chronic obstructive pulmonary disease	16.91	14.16	15	32409	46111	29873943
Gastrointestinal wall thinning	16.90	14.16	4	32420	16	29920038
Abdominal pain upper	16.85	14.16	26	32398	62525	29857529
Thrombotic microangiopathy	16.80	14.16	32	32392	8578	29911476
Hospitalisation	16.75	14.16	14	32410	44305	29875749
Gait disturbance	16.63	14.16	35	32389	74742	29845312
Aspartate aminotransferase	16.57	14.16	6	32418	126	29919928
Granulomatous dermatitis	16.55	14.16	7	32417	225	29919829
Blood bilirubin increased	16.53	14.16	81	32343	36555	29883499
Prostate cancer	16.47	14.16	3	32421	23954	29896100
Joint swelling	16.35	14.16	16	32408	46930	29873124
Acute lymphocytic leukaemia recurrent	16.03	14.16	17	32407	2650	29917404
Apraxia	15.96	14.16	12	32412	1190	29918864
Overdose	15.96	14.16	43	32381	84294	29835760
Flushing	15.91	14.16	6	32418	29486	29890568
Solar dermatitis	15.75	14.16	5	32419	69	29919985
Toxic skin eruption	15.71	14.16	36	32388	10979	29909075
Chronic granulomatous disease	15.71	14.16	4	32420	23	29920031
Periostosis	15.71	14.16	4	32420	23	29920031
Sinusitis fungal	15.67	14.16	8	32416	397	29919657
Bacterial infection	15.60	14.16	39	32385	12571	29907483
Hepatitis toxic	15.60	14.16	15	32409	2082	29917972
Chondritis	15.55	14.16	6	32418	151	29919903
Candida test positive	15.52	14.16	8	32416	405	29919649
Ephelides	15.49	14.16	5	32419	73	29919981
Chronic pulmonary histoplasmosis	15.41	14.16	3	32421	3	29920051
Lip ulceration	15.41	14.16	10	32414	783	29919271
Pneumonia cytomegaloviral	15.37	14.16	17	32407	2779	29917275
Nephrolithiasis	15.25	14.16	4	32420	24806	29895248
Hallucinations, mixed	15.23	14.16	16	32408	2467	29917587
Drug reaction with eosinophilia and systemic symptoms	15.03	14.16	6	32418	28482	29891572
Keratitis fungal	15.01	14.16	5	32419	81	29919973
Hypersensitivity	15.00	14.16	22	32402	54006	29866048
Escherichia sepsis	14.96	14.16	20	32404	3974	29916080
Product use issue	14.90	14.16	93	32331	45923	29874131
Arthritis	14.87	14.16	4	32420	24397	29895657
Pneumonia bacterial	14.84	14.16	32	32392	9371	29910683
Aplasia	14.79	14.16	20	32404	4017	29916037
Hypokalaemia	14.76	14.16	99	32325	50093	29869961
Mental disorder due to a general medical condition	14.73	14.16	6	32418	175	29919879
Venoocclusive liver disease	14.70	14.16	26	32398	6587	29913467
Staphylococcal sepsis	14.64	14.16	32	32392	9459	29910595
Loss of consciousness	14.62	14.16	41	32383	79334	29840720
Deep vein thrombosis	14.59	14.16	27	32397	60474	29859580
Necrotising ulcerative gingivostomatitis	14.58	14.16	5	32419	89	29919965
Blood beta-D-glucan increased	14.44	14.16	8	32416	469	29919585
Brain herniation	14.43	14.16	19	32405	3721	29916333
Abdominal discomfort	14.41	14.16	19	32405	48772	29871282
Injury	14.35	14.16	3	32421	21728	29898326
Off label use	14.33	14.16	362	32062	248928	29671126
Disseminated aspergillosis	14.32	14.16	5	32419	94	29919960
Penicillium infection	14.32	14.16	5	32419	94	29919960

Pharmacologic Action:

Source	Code	Description
ATC	J02AC03	ANTIINFECTIVES FOR SYSTEMIC USE ANTIMYCOTICS FOR SYSTEMIC USE ANTIMYCOTICS FOR SYSTEMIC USE Triazole derivatives
FDA CS	M0002083	Azoles
MeSH PA	D058888	14-alpha Demethylase Inhibitors
MeSH PA	D000890	Anti-Infective Agents
MeSH PA	D000935	Antifungal Agents
MeSH PA	D065692	Cytochrome P-450 CYP3A Inhibitors
MeSH PA	D065607	Cytochrome P-450 Enzyme Inhibitors
MeSH PA	D004791	Enzyme Inhibitors
MeSH PA	D006727	Hormone Antagonists
MeSH PA	D065606	Metabolic Side Effects of Drugs and Substances
MeSH PA	D065088	Steroid Synthesis Inhibitors
FDA EPC	N0000175487	Azole Antifungal
CHEBI has role	CHEBI:50183	cytochrome p450 inhibitor
FDA MoA	N0000182140	Cytochrome P450 2C19 Inhibitors
FDA MoA	N0000182141	Cytochrome P450 3A4 Inhibitors
FDA MoA	N0000185504	Cytochrome P450 2C9 Inhibitors

Drug Use (View source of the data)

Disease	Relation	SNOMED_ID	DOID
Invasive pulmonary aspergillosis	indication	3214003
Candidiasis of the esophagus	indication	20639004	DOID:13146
Fusarium infection	indication	64250002
Disseminated candidiasis	indication	70572005
Candidemia	indication	432261003
Fungal Infection due to Scedosporium Apiospermum	indication
Fungal Infection due to Fusarium Solani	indication
Oropharyngeal Candidiasis	off-label use
Hypocalcemia	contraindication	5291005
Torsades de pointes	contraindication	31722008
Hypokalemia	contraindication	43339004
Cardiomyopathy	contraindication	85898001	DOID:0050700
Prolonged QT interval	contraindication	111975006
Hypomagnesemia	contraindication	190855004
Impaired renal function disorder	contraindication	197663003
Disease of liver	contraindication	235856003	DOID:409
Pregnancy, function	contraindication	289908002
Visual impairment	contraindication	397540003
Breastfeeding (mother)	contraindication	413712001
Poor metabolizer due to cytochrome p450 CYP2C19 variant	contraindication	424500005
Congenital long QT syndrome	contraindication	442917000

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation level	Dissociation constant	Type (acidic/basic)
pKa1	13.93	acidic
pKa2	2.85	Basic
pKa3	1.42	Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

Formulation strength	Trade name	Applicant	Application number	Approval date	Type	Dose form	Route	Exclusivity date	Description
200MG	VFEND	PF PRISM CV	N021266	May 24, 2002	RX	TABLET	ORAL	Jan. 29, 2022	NEW PATIENT POPULATION
50MG	VFEND	PF PRISM CV	N021266	May 24, 2002	RX	TABLET	ORAL	Jan. 29, 2022	NEW PATIENT POPULATION
200MG/VIAL	VFEND	PF PRISM CV	N021267	May 24, 2002	RX	INJECTABLE	INTRAVENOUS	Jan. 29, 2022	NEW PATIENT POPULATION
200MG/5ML	VFEND	PF PRISM CV	N021630	Dec. 19, 2003	RX	FOR SUSPENSION	ORAL	Jan. 29, 2022	NEW PATIENT POPULATION

Bioactivity Summary:

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Mechanism action	Bioact source	MoA source
Cytochrome P450 3A4	Enzyme	P08684	CP3A4_HUMAN		IC50	4.89		CHEMBL
Cytochrome P450 2C9	Enzyme	P11712	CP2C9_HUMAN		IC50	4.85		CHEMBL
Cytochrome P450 2C19	Enzyme	P33261	CP2CJ_HUMAN		IC50	4.82		CHEMBL
Lanosterol 14-alpha demethylase	Enzyme		CP51_CANAL	INHIBITOR	MIC	8.73		WOMBAT-PK	CHEMBL
Lanosterol 14-alpha demethylase	Enzyme		CP51_MYCTU		MIC	5.84		WOMBAT-PK
14-alpha sterol demethylase	Enzyme		Q96W81_ASPFM		Kd	6.37		CHEMBL
14-alpha sterol demethylase Cyp51A	Enzyme		Q4WNT5_ASPFU		Kd	5.44		CHEMBL

External reference:

ID	Source
4021347	VUID
N0000148767	NUI
D00578	KEGG_DRUG
4021347	VANDF
C0532517	UMLSCUI
CHEBI:10023	CHEBI
VOR	PDB_CHEM_ID
CHEMBL638	ChEMBL_ID
D065819	MESH_DESCRIPTOR_UI
7269	INN_ID
JFU09I87TR	UNII
71616	PUBCHEM_CID
DB00582	DRUGBANK_ID
121243	RXNORM
16711	MMSL
179944	MMSL
43734	MMSL
d04803	MMSL
009650	NDDF
385469007	SNOMEDCT_US
386116008	SNOMEDCT_US

Pharmaceutical products:

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
VFEND	HUMAN PRESCRIPTION DRUG LABEL	1	0049-3160	POWDER, FOR SUSPENSION	40 mg	ORAL	NDA	34 sections
VFEND	HUMAN PRESCRIPTION DRUG LABEL	1	0049-3170	TABLET, FILM COATED	50 mg	ORAL	NDA	34 sections
VFEND	HUMAN PRESCRIPTION DRUG LABEL	1	0049-3180	TABLET, FILM COATED	200 mg	ORAL	NDA	34 sections
VFEND	HUMAN PRESCRIPTION DRUG LABEL	1	0049-3190	INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION	10 mg	INTRAVENOUS	NDA	34 sections
VFEND	HUMAN PRESCRIPTION DRUG LABEL	1	0049-3190	INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION	10 mg	INTRAVENOUS	NDA	34 sections
VFEND	HUMAN PRESCRIPTION DRUG LABEL	1	0049-3190	INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION	10 mg	INTRAVENOUS	NDA	34 sections
VFEND	HUMAN PRESCRIPTION DRUG LABEL	1	0049-4190	INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION	10 mg	INTRAVENOUS	NDA	33 sections
Voriconazole	HUMAN PRESCRIPTION DRUG LABEL	1	0378-1626	TABLET, FILM COATED	50 mg	ORAL	ANDA	31 sections
Voriconazole	HUMAN PRESCRIPTION DRUG LABEL	1	0378-1640	TABLET, FILM COATED	200 mg	ORAL	ANDA	31 sections
Voriconazole	HUMAN PRESCRIPTION DRUG LABEL	1	0781-3416	INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION	10 mg	INTRAVENOUS	ANDA	30 sections
voriconazole	HUMAN PRESCRIPTION DRUG LABEL	1	0781-5667	TABLET, FILM COATED	50 mg	ORAL	ANDA	30 sections
voriconazole	HUMAN PRESCRIPTION DRUG LABEL	1	0781-5668	TABLET, FILM COATED	200 mg	ORAL	ANDA	30 sections
voriconazole	HUMAN PRESCRIPTION DRUG LABEL	1	0904-6471	TABLET, FILM COATED	200 mg	ORAL	ANDA	30 sections
voriconazole	HUMAN PRESCRIPTION DRUG LABEL	1	0904-6596	TABLET	50 mg	ORAL	ANDA	28 sections
Voriconazole	HUMAN PRESCRIPTION DRUG LABEL	1	0904-7024	TABLET	200 mg	ORAL	ANDA	27 sections
Voriconazole	Human Prescription Drug Label	1	27241-062	TABLET	50 mg	ORAL	ANDA	27 sections
Voriconazole	Human Prescription Drug Label	1	27241-063	TABLET	200 mg	ORAL	ANDA	27 sections
Voriconazole	HUMAN PRESCRIPTION DRUG LABEL	1	39822-1077	INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION	10 mg	INTRAVENOUS	NDA	29 sections
voriconazole	HUMAN PRESCRIPTION DRUG LABEL	1	40032-038	SUSPENSION	40 mg	ORAL	ANDA	29 sections
voriconazole	HUMAN PRESCRIPTION DRUG LABEL	1	40032-088	TABLET, FILM COATED	50 mg	ORAL	ANDA	28 sections
voriconazole	HUMAN PRESCRIPTION DRUG LABEL	1	40032-089	TABLET, FILM COATED	200 mg	ORAL	ANDA	28 sections
VORICONULLZOLE	HUMAN PRESCRIPTION DRUG LABEL	1	43386-038	POWDER, FOR SUSPENSION	40 mg	ORAL	ANDA	29 sections
voriconazole	HUMAN PRESCRIPTION DRUG LABEL	1	43386-088	TABLET, FILM COATED	50 mg	ORAL	ANDA	29 sections
voriconazole	HUMAN PRESCRIPTION DRUG LABEL	1	43386-089	TABLET, FILM COATED	200 mg	ORAL	ANDA	29 sections
Voriconazole	HUMAN PRESCRIPTION DRUG LABEL	1	43547-377	TABLET, COATED	50 mg	ORAL	ANDA	18 sections
Voriconazole	HUMAN PRESCRIPTION DRUG LABEL	1	43547-378	TABLET, COATED	200 mg	ORAL	ANDA	18 sections
VORICONULLZOLE	HUMAN PRESCRIPTION DRUG LABEL	1	47781-466	INJECTION, POWDER, FOR SOLUTION	10 mg	INTRAVENOUS	ANDA	27 sections
Voriconazole	HUMAN PRESCRIPTION DRUG LABEL	1	51079-164	TABLET, FILM COATED	50 mg	ORAL	ANDA	31 sections
Voriconazole	HUMAN PRESCRIPTION DRUG LABEL	1	51079-165	TABLET, FILM COATED	200 mg	ORAL	ANDA	31 sections
voriconazole	HUMAN PRESCRIPTION DRUG LABEL	1	51407-133	TABLET, FILM COATED	200 mg	ORAL	ANDA	28 sections